Micardis

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HypertensionStrokeCardiovascular DiseaseEssential Hypertension

566 competitors in Hypertension

#DrugCompanyPhaseTrials

1

Micardis

Boehringer Ingelheim

Approved

32

Edarbi

Takeda

Preclinical

103

Benicar

Novartis

Preclinical

74

Apresoline

Novartis

Preclinical

75

Edarbi

Takeda

Preclinical

46

Alphagan

AbbVie

Preclinical

—7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

28

Avastin

BBio-Thera Solutions

Preclinical

19

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

110

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blood Pressure4 trials

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Completed·Boehringer Ingelheim··NCT02242331·19,805 enrolled

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Completed·Boehringer Ingelheim··NCT00879411·670 enrolled

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

Completed·Boehringer Ingelheim··NCT02242864·1,527 enrolled

Show 1 more trial

Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study

Completed·HHeart Care Foundation·Phase 4·NCT00421863·1,111 enrolled

Hypertension3 trials

Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

Completed·Boehringer Ingelheim··NCT02238275·8,135 enrolled

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

Completed·Boehringer Ingelheim··NCT02242357·14,553 enrolled

Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

Completed·Boehringer Ingelheim··NCT02202525·2,148 enrolled

Essential Hypertension2 trials

Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02242825·8,148 enrolled

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Completed·Boehringer Ingelheim··NCT02176850·19,870 enrolled

CAR1 trial

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

Completed·Boehringer Ingelheim·Phase 4·NCT00242814·100 enrolled

Rehabilitation1 trial

Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Completed·Boehringer Ingelheim··NCT02262611·266 enrolled

5 more indications

Adult1 trial

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

Completed·PPharmtechnology LLC·Phase 1·NCT03705533·26 enrolled

Cardiovascular Disease1 trial

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Completed·Boehringer Ingelheim··NCT02262637·4,814 enrolled

Stroke1 trial

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Completed·Boehringer Ingelheim·Phase 4·NCT00153062·20,332 enrolled

Overweight1 trial

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Completed·Boehringer Ingelheim·Phase 2·NCT00146289·138 enrolled

Cardiovascular Events1 trial

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

Terminated·KKyoto Prefectural University of Medicine·N/A·NCT00863980·1,500 enrolled

Details

Drug Info

Related News